Predicting outcome based on swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection
The aim of this study was to study the effectiveness of the Swenerton score in assessing extent of disease as an independent prognostic and predictive factor in patients with metastatic breast cancer (MBC) who receive high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell transplant (...
Gespeichert in:
| Veröffentlicht in: | Biology of blood and marrow transplantation 2003-05, Vol.9 (5), p.330-340 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 340 |
|---|---|
| container_issue | 5 |
| container_start_page | 330 |
| container_title | Biology of blood and marrow transplantation |
| container_volume | 9 |
| creator | Montemurro, Filippo Rondón, Gabriela Munsell, Mark Smith, Terry L Donato, Michele L Gajewski, James L Rahman, Zia U Buzdar, Aman U Champlin, Richard E Ueno, Naoto T |
| description | The aim of this study was to study the effectiveness of the Swenerton score in assessing extent of disease as an independent prognostic and predictive factor in patients with metastatic breast cancer (MBC) who receive high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell transplant (AHSCT). Two-hundred thirty-two patients with MBC underwent HDCT. Extent of disease was assessed quantitatively using the Swenerton score. A retrospective analysis was performed using Cox proportional hazards regression and logistic regression models. One hundred three (44%) patients had a complete response (CR) after HDCT. Bone marrow as source of hematopoietic stem cells, hormone-receptor-negative status, and visceral involvement correlated with both worse overall survival (OS) and progression-free survival (PFS). Short disease-free interval, multiple sites of metastatic disease, and less than 50% reduction in the Swenerton Score during induction chemotherapy correlated with worse OS. Patients in CR at the time of HDCT had better PFS than patients in partial response, stable disease, or progressive disease. Fifty-six patients who underwent conversion to CR after HDCT had a similar median OS (not reached
v 74 months;
P = .51) and PFS duration (22
v 44 months;
P = .15) as patients who received HDCT after a CR to standard-dose chemotherapy (SDCT). Conversion to CR was predicted by a ≥50% reduction in the Swenerton score during SDCT (odds ratio [OR] 3.32,
P < .01) and soft-tissue disease (OR 4.08,
P < .01). The presence of multiple metastatic sites predicted decreased probability of conversion to CR (OR 0.34,
P < .01). The Swenerton score provides a thorough estimate of disease extent, and reduction of Swenerton score by SDCT is potentially useful for selecting the optimal candidates for HDCT trials who may achieve long-term disease control. |
| doi_str_mv | 10.1016/S1083-8791(03)00088-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73317238</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1083879103000880</els_id><sourcerecordid>73317238</sourcerecordid><originalsourceid>FETCH-LOGICAL-c363t-b6664a21833f19564542f40ce56daa557b1c6344547fca4572244676d2a57e973</originalsourceid><addsrcrecordid>eNqFUcuO1DAQtBCIXQY-AdQnBIeAHcd2hgtCK17SSiABZ8txOhOjxA62w2p_ky_CmZkVR04ut8tV3V2EPGX0FaNMvv7GaMurVu3ZC8pfUkrbtqL3yCUTNa-k4PJ-wXeUC_IopZ-FpJp2_5BcsFpJ2bb8kvz5GrF3Njt_gLBmG2aEziTsIXhIN-gx5g3ZEBGch8Vkhz4nuHF5hBmzSbmULHQRCwRrvMUIq-8xHsKmOrrDWPUhIdgR55BHjGa5BeN7MGsOUziENUF5MjksweEmljLOYHGaIEfj0zIZv7kE_wbcvEzOHi8JhhDvOoKEE9qt_Jg8GMyU8Mn53JEfH95_v_pUXX_5-Pnq3XVlueS56qSUjalZy_nA9kI2oqmHhloUsjdGCNUxK3lTymqwphGqrptGKtnXRijcK74jz0-6Swy_VkxZzy5tTRuPZSStOGeq5m0hihPRxpBSxEEv0c0m3mpG9RamPoapt6Q05foYZgE78uxssHYz9v9-ndMrhLcnApYxfzuMOtmyC1sSjWUXug_uPxZ_AYiqtVg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73317238</pqid></control><display><type>article</type><title>Predicting outcome based on swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Montemurro, Filippo ; Rondón, Gabriela ; Munsell, Mark ; Smith, Terry L ; Donato, Michele L ; Gajewski, James L ; Rahman, Zia U ; Buzdar, Aman U ; Champlin, Richard E ; Ueno, Naoto T</creator><creatorcontrib>Montemurro, Filippo ; Rondón, Gabriela ; Munsell, Mark ; Smith, Terry L ; Donato, Michele L ; Gajewski, James L ; Rahman, Zia U ; Buzdar, Aman U ; Champlin, Richard E ; Ueno, Naoto T</creatorcontrib><description>The aim of this study was to study the effectiveness of the Swenerton score in assessing extent of disease as an independent prognostic and predictive factor in patients with metastatic breast cancer (MBC) who receive high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell transplant (AHSCT). Two-hundred thirty-two patients with MBC underwent HDCT. Extent of disease was assessed quantitatively using the Swenerton score. A retrospective analysis was performed using Cox proportional hazards regression and logistic regression models. One hundred three (44%) patients had a complete response (CR) after HDCT. Bone marrow as source of hematopoietic stem cells, hormone-receptor-negative status, and visceral involvement correlated with both worse overall survival (OS) and progression-free survival (PFS). Short disease-free interval, multiple sites of metastatic disease, and less than 50% reduction in the Swenerton Score during induction chemotherapy correlated with worse OS. Patients in CR at the time of HDCT had better PFS than patients in partial response, stable disease, or progressive disease. Fifty-six patients who underwent conversion to CR after HDCT had a similar median OS (not reached
v 74 months;
P = .51) and PFS duration (22
v 44 months;
P = .15) as patients who received HDCT after a CR to standard-dose chemotherapy (SDCT). Conversion to CR was predicted by a ≥50% reduction in the Swenerton score during SDCT (odds ratio [OR] 3.32,
P < .01) and soft-tissue disease (OR 4.08,
P < .01). The presence of multiple metastatic sites predicted decreased probability of conversion to CR (OR 0.34,
P < .01). The Swenerton score provides a thorough estimate of disease extent, and reduction of Swenerton score by SDCT is potentially useful for selecting the optimal candidates for HDCT trials who may achieve long-term disease control.</description><identifier>ISSN: 1083-8791</identifier><identifier>EISSN: 1523-6536</identifier><identifier>DOI: 10.1016/S1083-8791(03)00088-0</identifier><identifier>PMID: 12766883</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Antineoplastic Agents - therapeutic use ; Autologous transplantation ; Breast neoplasm ; Breast Neoplasms - diagnosis ; Breast Neoplasms - mortality ; Breast Neoplasms - therapy ; Female ; Hematopoietic Stem Cell Transplantation - mortality ; High-dose chemotherapy ; Humans ; Middle Aged ; Multivariate Analysis ; Neoplasm Metastasis - diagnosis ; Patient Selection ; Predictive Value of Tests ; Prognosis ; Remission Induction ; Retrospective Studies ; Severity of Illness Index ; Survival Analysis ; Transplantation, Autologous ; Treatment Outcome</subject><ispartof>Biology of blood and marrow transplantation, 2003-05, Vol.9 (5), p.330-340</ispartof><rights>2003 American Society for Blood and Marrow Transplantation</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c363t-b6664a21833f19564542f40ce56daa557b1c6344547fca4572244676d2a57e973</citedby><cites>FETCH-LOGICAL-c363t-b6664a21833f19564542f40ce56daa557b1c6344547fca4572244676d2a57e973</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S1083-8791(03)00088-0$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>315,782,786,3552,27931,27932,46002</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12766883$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Montemurro, Filippo</creatorcontrib><creatorcontrib>Rondón, Gabriela</creatorcontrib><creatorcontrib>Munsell, Mark</creatorcontrib><creatorcontrib>Smith, Terry L</creatorcontrib><creatorcontrib>Donato, Michele L</creatorcontrib><creatorcontrib>Gajewski, James L</creatorcontrib><creatorcontrib>Rahman, Zia U</creatorcontrib><creatorcontrib>Buzdar, Aman U</creatorcontrib><creatorcontrib>Champlin, Richard E</creatorcontrib><creatorcontrib>Ueno, Naoto T</creatorcontrib><title>Predicting outcome based on swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection</title><title>Biology of blood and marrow transplantation</title><addtitle>Biol Blood Marrow Transplant</addtitle><description>The aim of this study was to study the effectiveness of the Swenerton score in assessing extent of disease as an independent prognostic and predictive factor in patients with metastatic breast cancer (MBC) who receive high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell transplant (AHSCT). Two-hundred thirty-two patients with MBC underwent HDCT. Extent of disease was assessed quantitatively using the Swenerton score. A retrospective analysis was performed using Cox proportional hazards regression and logistic regression models. One hundred three (44%) patients had a complete response (CR) after HDCT. Bone marrow as source of hematopoietic stem cells, hormone-receptor-negative status, and visceral involvement correlated with both worse overall survival (OS) and progression-free survival (PFS). Short disease-free interval, multiple sites of metastatic disease, and less than 50% reduction in the Swenerton Score during induction chemotherapy correlated with worse OS. Patients in CR at the time of HDCT had better PFS than patients in partial response, stable disease, or progressive disease. Fifty-six patients who underwent conversion to CR after HDCT had a similar median OS (not reached
v 74 months;
P = .51) and PFS duration (22
v 44 months;
P = .15) as patients who received HDCT after a CR to standard-dose chemotherapy (SDCT). Conversion to CR was predicted by a ≥50% reduction in the Swenerton score during SDCT (odds ratio [OR] 3.32,
P < .01) and soft-tissue disease (OR 4.08,
P < .01). The presence of multiple metastatic sites predicted decreased probability of conversion to CR (OR 0.34,
P < .01). The Swenerton score provides a thorough estimate of disease extent, and reduction of Swenerton score by SDCT is potentially useful for selecting the optimal candidates for HDCT trials who may achieve long-term disease control.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Autologous transplantation</subject><subject>Breast neoplasm</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - therapy</subject><subject>Female</subject><subject>Hematopoietic Stem Cell Transplantation - mortality</subject><subject>High-dose chemotherapy</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Metastasis - diagnosis</subject><subject>Patient Selection</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Remission Induction</subject><subject>Retrospective Studies</subject><subject>Severity of Illness Index</subject><subject>Survival Analysis</subject><subject>Transplantation, Autologous</subject><subject>Treatment Outcome</subject><issn>1083-8791</issn><issn>1523-6536</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUcuO1DAQtBCIXQY-AdQnBIeAHcd2hgtCK17SSiABZ8txOhOjxA62w2p_ky_CmZkVR04ut8tV3V2EPGX0FaNMvv7GaMurVu3ZC8pfUkrbtqL3yCUTNa-k4PJ-wXeUC_IopZ-FpJp2_5BcsFpJ2bb8kvz5GrF3Njt_gLBmG2aEziTsIXhIN-gx5g3ZEBGch8Vkhz4nuHF5hBmzSbmULHQRCwRrvMUIq-8xHsKmOrrDWPUhIdgR55BHjGa5BeN7MGsOUziENUF5MjksweEmljLOYHGaIEfj0zIZv7kE_wbcvEzOHi8JhhDvOoKEE9qt_Jg8GMyU8Mn53JEfH95_v_pUXX_5-Pnq3XVlueS56qSUjalZy_nA9kI2oqmHhloUsjdGCNUxK3lTymqwphGqrptGKtnXRijcK74jz0-6Swy_VkxZzy5tTRuPZSStOGeq5m0hihPRxpBSxEEv0c0m3mpG9RamPoapt6Q05foYZgE78uxssHYz9v9-ndMrhLcnApYxfzuMOtmyC1sSjWUXug_uPxZ_AYiqtVg</recordid><startdate>20030501</startdate><enddate>20030501</enddate><creator>Montemurro, Filippo</creator><creator>Rondón, Gabriela</creator><creator>Munsell, Mark</creator><creator>Smith, Terry L</creator><creator>Donato, Michele L</creator><creator>Gajewski, James L</creator><creator>Rahman, Zia U</creator><creator>Buzdar, Aman U</creator><creator>Champlin, Richard E</creator><creator>Ueno, Naoto T</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030501</creationdate><title>Predicting outcome based on swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection</title><author>Montemurro, Filippo ; Rondón, Gabriela ; Munsell, Mark ; Smith, Terry L ; Donato, Michele L ; Gajewski, James L ; Rahman, Zia U ; Buzdar, Aman U ; Champlin, Richard E ; Ueno, Naoto T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c363t-b6664a21833f19564542f40ce56daa557b1c6344547fca4572244676d2a57e973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Autologous transplantation</topic><topic>Breast neoplasm</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - therapy</topic><topic>Female</topic><topic>Hematopoietic Stem Cell Transplantation - mortality</topic><topic>High-dose chemotherapy</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Metastasis - diagnosis</topic><topic>Patient Selection</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Remission Induction</topic><topic>Retrospective Studies</topic><topic>Severity of Illness Index</topic><topic>Survival Analysis</topic><topic>Transplantation, Autologous</topic><topic>Treatment Outcome</topic><toplevel>online_resources</toplevel><creatorcontrib>Montemurro, Filippo</creatorcontrib><creatorcontrib>Rondón, Gabriela</creatorcontrib><creatorcontrib>Munsell, Mark</creatorcontrib><creatorcontrib>Smith, Terry L</creatorcontrib><creatorcontrib>Donato, Michele L</creatorcontrib><creatorcontrib>Gajewski, James L</creatorcontrib><creatorcontrib>Rahman, Zia U</creatorcontrib><creatorcontrib>Buzdar, Aman U</creatorcontrib><creatorcontrib>Champlin, Richard E</creatorcontrib><creatorcontrib>Ueno, Naoto T</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biology of blood and marrow transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Montemurro, Filippo</au><au>Rondón, Gabriela</au><au>Munsell, Mark</au><au>Smith, Terry L</au><au>Donato, Michele L</au><au>Gajewski, James L</au><au>Rahman, Zia U</au><au>Buzdar, Aman U</au><au>Champlin, Richard E</au><au>Ueno, Naoto T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predicting outcome based on swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection</atitle><jtitle>Biology of blood and marrow transplantation</jtitle><addtitle>Biol Blood Marrow Transplant</addtitle><date>2003-05-01</date><risdate>2003</risdate><volume>9</volume><issue>5</issue><spage>330</spage><epage>340</epage><pages>330-340</pages><issn>1083-8791</issn><eissn>1523-6536</eissn><abstract>The aim of this study was to study the effectiveness of the Swenerton score in assessing extent of disease as an independent prognostic and predictive factor in patients with metastatic breast cancer (MBC) who receive high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell transplant (AHSCT). Two-hundred thirty-two patients with MBC underwent HDCT. Extent of disease was assessed quantitatively using the Swenerton score. A retrospective analysis was performed using Cox proportional hazards regression and logistic regression models. One hundred three (44%) patients had a complete response (CR) after HDCT. Bone marrow as source of hematopoietic stem cells, hormone-receptor-negative status, and visceral involvement correlated with both worse overall survival (OS) and progression-free survival (PFS). Short disease-free interval, multiple sites of metastatic disease, and less than 50% reduction in the Swenerton Score during induction chemotherapy correlated with worse OS. Patients in CR at the time of HDCT had better PFS than patients in partial response, stable disease, or progressive disease. Fifty-six patients who underwent conversion to CR after HDCT had a similar median OS (not reached
v 74 months;
P = .51) and PFS duration (22
v 44 months;
P = .15) as patients who received HDCT after a CR to standard-dose chemotherapy (SDCT). Conversion to CR was predicted by a ≥50% reduction in the Swenerton score during SDCT (odds ratio [OR] 3.32,
P < .01) and soft-tissue disease (OR 4.08,
P < .01). The presence of multiple metastatic sites predicted decreased probability of conversion to CR (OR 0.34,
P < .01). The Swenerton score provides a thorough estimate of disease extent, and reduction of Swenerton score by SDCT is potentially useful for selecting the optimal candidates for HDCT trials who may achieve long-term disease control.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>12766883</pmid><doi>10.1016/S1083-8791(03)00088-0</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-8791 |
| ispartof | Biology of blood and marrow transplantation, 2003-05, Vol.9 (5), p.330-340 |
| issn | 1083-8791 1523-6536 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73317238 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aged Antineoplastic Agents - therapeutic use Autologous transplantation Breast neoplasm Breast Neoplasms - diagnosis Breast Neoplasms - mortality Breast Neoplasms - therapy Female Hematopoietic Stem Cell Transplantation - mortality High-dose chemotherapy Humans Middle Aged Multivariate Analysis Neoplasm Metastasis - diagnosis Patient Selection Predictive Value of Tests Prognosis Remission Induction Retrospective Studies Severity of Illness Index Survival Analysis Transplantation, Autologous Treatment Outcome |
| title | Predicting outcome based on swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T11%3A54%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predicting%20outcome%20based%20on%20swenerton%20score%20in%20patients%20with%20metastatic%20breast%20cancer%20undergoing%20high-dose%20chemotherapy%20and%20autologous%20hematopoietic%20stem%20cell%20transplantation:%20implications%20for%20patient%20selection&rft.jtitle=Biology%20of%20blood%20and%20marrow%20transplantation&rft.au=Montemurro,%20Filippo&rft.date=2003-05-01&rft.volume=9&rft.issue=5&rft.spage=330&rft.epage=340&rft.pages=330-340&rft.issn=1083-8791&rft.eissn=1523-6536&rft_id=info:doi/10.1016/S1083-8791(03)00088-0&rft_dat=%3Cproquest_cross%3E73317238%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73317238&rft_id=info:pmid/12766883&rft_els_id=S1083879103000880&rfr_iscdi=true |